2142 Stock Overview
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
HBM Holdings Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$1.38 |
52 Week High | HK$2.64 |
52 Week Low | HK$1.33 |
Beta | 1.51 |
1 Month Change | -17.86% |
3 Month Change | -12.10% |
1 Year Change | -34.91% |
3 Year Change | -84.60% |
5 Year Change | n/a |
Change since IPO | -87.48% |
Recent News & Updates
Recent updates
HBM Holdings Limited (HKG:2142) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Jan 01We're Not Very Worried About HBM Holdings' (HKG:2142) Cash Burn Rate
Feb 08HBM Holdings (HKG:2142) Is In A Strong Position To Grow Its Business
May 30Revenue Downgrade: Here's What Analysts Forecast For HBM Holdings Limited (HKG:2142)
Apr 07Here's What Analysts Are Forecasting For HBM Holdings Limited (HKG:2142) After Its Full-Year Results
Mar 31What Type Of Shareholders Own The Most Number of HBM Holdings Limited (HKG:2142) Shares?
Mar 10Shareholder Returns
2142 | HK Biotechs | HK Market | |
---|---|---|---|
7D | -7.4% | -5.5% | -1.2% |
1Y | -34.9% | -43.0% | -12.2% |
Return vs Industry: 2142 exceeded the Hong Kong Biotechs industry which returned -42.8% over the past year.
Return vs Market: 2142 underperformed the Hong Kong Market which returned -13.4% over the past year.
Price Volatility
2142 volatility | |
---|---|
2142 Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 7.3% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2142's share price has been volatile over the past 3 months.
Volatility Over Time: 2142's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 167 | Jingsong Wang | https://www.harbourbiomed.com |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9378 for the treatment of Asthma; and HBM1020, HBM1007, HBM1022, HBM7022, HBM9027, HBM9033, HBM7004, HBM1047, and HBM9014 for the treatment of solid tumors.
HBM Holdings Limited Fundamentals Summary
2142 fundamental statistics | |
---|---|
Market cap | HK$1.01b |
Earnings (TTM) | -HK$479.07m |
Revenue (TTM) | HK$422.57m |
2.4x
P/S Ratio-2.1x
P/E RatioIs 2142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2142 income statement (TTM) | |
---|---|
Revenue | US$54.03m |
Cost of Revenue | US$85.00k |
Gross Profit | US$53.94m |
Other Expenses | US$115.19m |
Earnings | -US$61.25m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -0.084 |
Gross Margin | 99.84% |
Net Profit Margin | -113.37% |
Debt/Equity Ratio | 80.7% |
How did 2142 perform over the long term?
See historical performance and comparison